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Abstract 
The use of left ventricular assist devices (LVAD) provides a treatment strategy for 
advanced heart failure patients to prolong life and serve as a mediator (bridge to 
transplant) until an organ becomes available in patients considered suitable 
candidates for heart transplantation.  The use of LVAD therapy is complicated by 
the constant risk of bleeding and thrombotic events.  We reviewed and analyzed 
the effectiveness of our current heparin protocol with respect to overall 
anticoagulation and time in therapeutic range (TTR).  Our analysis demonstrated 
that patients did not achieve therapeutic anticoagulation for at least 24 hours 
following initiation of heparin and that only 40% of the time patients were 
considered therapeutic.  Even after patients achieved a therapeutic activated 
plasma thromboplastin time (aPTT) TTR was only approximately 50% with less 
than 50% of tests resulting within range.  Individual centers should perform 
ongoing assessment of effectiveness of individual heparin protocol for LVAD 
patients to ensure anticoagulation is optimized in these highly complex patients.   
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Introduction 
Left ventricular assist devices have become an essential component in heart 
failure management.1-5  While heart transplant remains the only definitive therapy 
for patients with advanced heart failure (AHF), left ventricular assist device (LVAD) 
therapy provides a viable option for patients deemed candidates for transplant or 
as destination therapy in ineligible candidates.1-5  Unfortunately, despite significant 
advancements in LVAD therapy, its use continues to be complicated by bleeding 
risks and pump thrombosis.6-10  The use of anticoagulation therapy following LVAD 
implantation remains non-standardized, varying significantly amongst various 
centers and continues to evolve with emerging data.10 In 2014, a report 
demonstrated an unexpected significant increase in the rate of pump thrombosis 
and strokes in patients implanted with the Heartmate II, a continuous-flow LVAD at 
three major LVAD programs.11  Unfortunately, the exact etiology for pump 
thrombosis was not established but potential causes could relate to changes in 
anticoagulation practices, surgical technique, and change in pump design or 
manufacturing.  
The manufacturers for the Heartware and HeartMate II devices provide 
recommendations regarding anticoagulation and antiplatelet therapy but do not 
provide strategies to achieve and maintain these parameters.12-13 During the study 
period, we utilized the atrial fibrillation (AF)/stroke prophylaxis heparin protocol 
following LVAD placement with a therapeutic aPTT range defined as 60-80 
seconds.  The use of this protocol has not been formally reviewed in this patient 
population and the potential risks/benefits remain unclear.  With continued concern 
surrounding the risk of pump thrombosis and strokes within LVAD patients, our 
center wanted to evaluate current systemic intravenous anticoagulation practices 
to assess overall management in an effort to reduce the risk for pump thrombosis 
and strokes. 
Methods 
This was a single-center, retrospective descriptive analysis conducted at an 
academic medical center.  Patients >18 years of age who were implanted or 
readmitted with a Heartmate II or Heartware LVAD between January 2013 and 
June 2015 were considered for inclusion.  Patients were excluded from the 
analysis if they were not initiated on the AF/stroke prophylaxis heparin protocol or 
if they achieved therapeutic anticoagulation on fixed dose heparin.  Additionally, 
patients requiring an LVAD exchange were excluded from analyses following 
pump exchange but were considered for inclusion at any point prior to the 
exchange.  The therapeutic range of the AF/stroke prophylaxis protocol was 
defined as 60-80 seconds.  Adjustments to goal range were considered deviations 
from standard therapy and excluded from analysis.  Patients initiated on heparin 
protocol post-LVAD implantation were analyzed separately than patients 
readmitted and started on heparin protocol. In an effort to standardize heparin 
management, our institution utilizes adjust body weight  
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Heparin initiation time was defined as end anesthesia time until initiation of 
heparin, while heparin protocol initiation was end anesthesia time until initiation of 
AF/stroke prophylaxis protocol.  When patients were transitioned from fixed dose 
heparin to AF/stroke prophylaxis protocol, both heparin rate immediately preceding 
transitioning to protocol and heparin rate (units/kg/hr) were recorded.  In addition 
to time in therapeutic range (TTR), we also assessed time subtherapeutic and 
supratherapeutic defined as aPTT ranges of 0 to 59.9 and 80.1 to 200.1, 
respectively. We also recorded percentage of aPTT tests within range, time from 
protocol initiation to first therapeutic aPTT value and heparin rate at the time of first 
therapeutic value.  Percentage of time subtherapeutic, therapeutic, and 
supratherapeutic were evaluated utilizing a modified version of the Rosendaal 
method which assesses percentage of aPTT values in range.14 
Survival, thrombosis and bleeding outcomes were also evaluated.  Bleeding 
events were assessed during heparin therapy and up to 48 hours after its 
discontinuation with an event being defined as an episode of internal or external 
bleeding leading to death, reoperation, permanent injury, or necessitating 
transfusion of more than 2 units of blood within a consecutive 24 hour periods.  To 
be classified as a bleeding event, patients were required to be actively on the 
specified heparin protocol.  Thrombosis endpoints were assessed from initiation of 
heparin therapy until the end of the study analysis.  Thrombosis endpoints 
included thrombus formation within the device or systemic events including 
cardioembolic stroke, thrombotic stroke/transient ischemic attack, myocardial 
infarction, deep vein thrombosis (DVT) or pulmonary embolism (PE).  All events 
were assessed through review of medical records, including progress, surgical, 
and radiographic reports.   
Results 
During the study time frame a total of 135 patients underwent LVAD implantation 
with 62 patients meeting the implanting group inclusion criteria.  Patients were 
excluded for the following reasons: achieved therapeutic aPTT on fixed dose 
heparin (n=26), utilized bivalirudin for anticoagulation (n=14), only received fixed 
dose heparin (n=9), did not receive anticoagulation (n=8) were not initiated on 
standard protocol (n=8), received less than24 hours of heparin (n=1).  Of the eight 
patients excluded from the analysis due to LVAD pump exchange four of the 
exchanges were the result of LVAD thrombosis.  Further evaluation identified that 
only one of the four device thrombosis were previously on the AF/stroke 
prophylaxis heparin protocol.  A total of 52 patients who were readmitted and 
initiated on heparin protocol and included in the readmission cohort.   
Baseline demographics are reported for patients included within both cohorts. 
(Table 1)  Patients were predominately male (initial: 84% and re-implant: 94.2%) 
who were more likely to be implanted with HeartMate II (initial: 80.6% and re-
implant: 80.8%) as compared to Heartware (initial: 19.4% and re-implant: 19.2%).  
Large discrepancies were noted between actual body weight and adjusted body 
weight within both cohorts.    
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Table 1. Baseline Demographics 
Baseline Demographics Initial Implant 
(n=62) 
Readmission 
(n=52) 
Age 54.2 years (27-73.8) 53.9 years (28.2-
71.3) 
Gender (male) 54 (87%) 49 (94.2%) 
Race 
Caucasian 
African American 
Other 
 
24 (38.7%) 
25 (40%) 
13 (20.1%) 
 
24 (46.2%) 
14 (26.9%) 
14 (26.9%) 
Weight 96.3 kg (53.8-180) 101.7 kg (67.5-
179.6) 
Heparin dosing weight 83.5 kg (56-133.5) 82.5 kg (58.0-123) 
Indication for LVAD 
Ischemic Cardiomyopathy 
Non-Ischemic Cardiomyopathy  
 
37 (59.7%) 
25 (40.3%) 
 
 
 
Type of LVAD 
Heartmate II 
HVAD 
 
50 (80.6%) 
12 (19.4%) 
 
42 (80.8%) 
10 (19.2%) 
 
Comorbidities 
Diabetes mellitus 
Atrial Fibrillation 
Respiratory Failure 
Renal Failure 
Liver failure 
Other 
 
21 (36%) 
20 (32.3%) 
9 (14.5%) 
21 (36%) 
5 (8.1%) 
32 (51.6%) 
 
 
Kg = kilogram; LVAD = left ventricular assist device;  
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Within the initial implantation cohort, 93.5% (n=58) of patients were discharged 
from the hospital while 4% required pump exchange or died. (Table 2)  A total of 8 
patients (12.9%) developed thrombus formation which was confirmed by radiologic 
studies at a subsequent point following LVAD implantation.  Bleeding events were 
demonstrated in 17.7% (n=11) of patients while receiving heparin.   
Table 2. Outcomes following initial implantation 
Outcomes – Initial Implantation (n=62) 
Survival 
Discharge from hospital 
Pump exchange 
Death 
 
58 (93.5%) 
2 (3.2%) 
2 (3.2%) 
 
Thrombus 8 (12.9%) 
Bleeding 11 (17.7%) 
Blood product utilization, median (Range) 
Red Blood Cell 
Fresh Frozen Plasma 
Platelet 
Cryoprecipitate 
 
6 (0-23) 
3 (0-12) 
2 (0-8) 
0 (0-4) 
 
Factor administration, n (%) 1 (2%) 
During initial LVAD implantation, heparin was initiated an average of 32.6 hours 
following completion of end anesthesia time. (Table 3)  Patients were initiated on 
protocol heparin nearly 64 hours later with average conversion of heparin rate from 
667.2 units/hr (100-1800) to 12.8 units/kg/hr (6-22).  An additional 32 hours was 
required from initiation of heparin protocol for patients to achieve their 1st 
therapeutic aPTT with an average heparin rate of 17 units/kg/hr.  Overall, patients 
were within therapeutic range 40% of the time during the initial implantation cohort.  
(Table 3) When patients weren’t therapeutic they were more frequently noted to be 
subtherapeutic (37.9%) as compared to supratherapeutic (16.7%).  
With respect to the readmission cohort, numerically, there was a similar protocol 
initiation rate (13.6 units/kg/hr) and heparin rate at 1st therapeutic aPTT value (16.7 
units/kg/hr) but patients achieved therapeutic aPTT nearly 3 hours earlier.  Despite 
this TTR was essentially unchanged at 44.2%.  (Table 3) Overall, patients were 
considered supratherapeutic only 13.2% of the time. 
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Table 3. Anticoagulation outcomes  
Anticoagulation   Initial Implantation 
(n=62) 
Readmission 
(n=52) 
Heparin initiation – post implant hours 32.6 (7.4-140.5)* N/A 
Heparin protocol initiation – post implant hours 96.2 (14.6-267.3) N/A 
Heparin rate prior to protocol conversion 
units/hour 
667.2 (100-1800)+ N/A 
Protocol initiation rate units/kg/hour 12.8 (6-22) 13.6 (7 – 16) 
Hours to 1st therapeutic aPTT (from protocol 
initiation)  
32.3 (2.9-86)¥ 29.0 (5.3 – 
93.7)¥ 
Heparin rate at 1st therapeutic aPTT units/kg/hour 17 (6-26) 16.7 (11 - 24) 
Hours in range (% of time) 
Subtherapeutic (0 - < 60) 
Therapeutic (60 – 80) 
Supratherapeutic (>80 – 200) 
 
37.9 (0 – 100) 
40.4 (0 – 85.2) 
16.7 (0 – 37.9) 
 
41.8 (6.7 – 84.2) 
44.2 (0 – 100) 
13.2 (0 – 37.1) 
 
aPTT tests in range (% of time) 
Subtherapeutic (0 - < 60) 
Therapeutic (60 – 80) 
Supratherapeutic (>80 – 200) 
 
41.9 (0 – 100) 
34.7 (0 – 75) 
19.8 (0 – 40) 
 
46.4 (16.7 – 
87.5) 
39.9 (0 – 100) 
14.3 (0 – 30.8) 
 
 
aPTT = activated partial thromboplastin time;  
* 4 patients were not initiated on fixed dose heparin  
+ 4 patients not initiated on fixed dose heparin; unable to equate fixed rate prior to 
protocol initiation 
¥ 2 patients (initial) and 1 patient (readmission) did not achieve therapeutic aPTT 
prior to heparin discontinuation 
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Regarding maintenance of therapeutic anticoagulation following achieving a 
therapeutic aPTT value the cohorts were nearly identical with 48.8% in the initial 
implantation and 52.3% in the readmission cohorts, respectively. (Table 4) 
Table 4. Time in therapeutic range once patient reaches first therapeutic 
aPTT 
 Initial Implantation 
(n=50)+ 
Readmission 
(n=52) * 
% hours within range 48.8 (0-96.9) 53.9 (14.4 – 100) 
% of tests in range 42.7 (0-75) 50.2 (0 – 100) 
+ 2 patient did not achieve therapeutic aPTT and time in therapeutic range was not 
calculated 
* 1 patient did not achieve therapeutic aPTT and time in therapeutic range was not 
calculated 
 
Discussion 
Our analysis demonstrated that patients were supratherapeutic following LVAD 
implantation only 16.7% of the time, likely owing to ongoing bleeding concern 
following implantation.  Despite overall totality of therapeutic heparin being 40%, 
after achieving a therapeutic aPTT the ongoing TTR only increased to 48.8%.  
Even with a relatively low TTR, the subsequent risk of thrombus (12.9%) was 
similar, albeit on the higher side, to what has been demonstrated in published 
literature.15,16  Patients were separated into two distinct groups as they represent 
vastly different management strategies.  Patients who are immediately post-
operative are at much higher bleeding risk, and careful consideration of 
anticoagulation must be taken.  Patients being readmitted on the other hand, are 
potentially at a higher risk of thrombus formation and might require more 
aggressive anticoagulation management.  Of the eight patients excluded from the 
analysis due to LVAD exchange, four were the result of device thrombosis but only 
one of the thrombosed devices previously received the evaluated protocol.  As this 
was a descriptive, retrospective  study assessing effectiveness of the heparin 
protocol to achieve and maintain therapeutic anticoagulation establishing a causal 
relationship to development of thrombosis was not possible.  
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The use of LVAD therapy has significantly improved the life span of advanced 
heart failure patients serving as destination therapy or as bridge to transplant, it is 
not without complications.1-5; 17  The optimal LVAD will provide cardiac support to 
heart failure patients while eliminating the need for a driveline, and reducing or 
eliminating the risk for thrombotic and bleeding events.  Vast strides have been 
made to further advance the pump design and with improved technology these 
complications may become obsolete.17  As pump technology continues to evolve 
optimization of anticoagulation and antiplatelet therapy has been shown to reduce 
the rate of pump thrombosis up to 50%.18  To capitalize on these findings the 
PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management 
(PREVENT) study was designed to establish whether a standardize approach for 
surgical implant technique, anticoagulation, and pump speeds following HMII 
implantation would reduce the risk of pump thrombosis.  Full adherence to implant 
techniques, anticoagulation and pump speeds significantly reduced the risk of 
pump thrombosis (1.9% vs. 8.9%; p <0.01) and the composite outcome 
(suspected thrombosis, hemolysis, and ischemic stroke) at 6 months (5.6% vs 
17.7%; p<0.01).19  Despite, the significant benefit noted with full adherence to key 
recommendations overall, the recommendations were inconsistently followed with 
78% adherence to surgical recommendations, 95% to heparin bridging, and 79% 
to pump speeds >=9,000 RPMs.19   
It is difficult to determine whether a specific recommendation from the PREVENT 
study had an impact on reduction in pump thrombosis as the study was not 
powered to assess individual components effect on pump thrombosis.  It could be 
argued that the anticoagulation and antiplatelet recommendations within 
PREVENT be strictly followed.  The median INR within the analysis was 2.1 (IQR 
1.9-2.3) but median time spent at a target range (2.0-2.5) was only 31% (IQR 
19%-44%).19  Unfortunately, a protocol for achieving and maintaining specific 
aPTT values was not discussed by the study investigators and the results 
regarding time within therapeutic range of heparin were not reported.   
Raschke et al. produced a landmark study demonstrating that heparin dosing 
based on patients’ body weight resulted in more rapid anticoagulation as well as 
fewer recurrent thrombotic events when compared to “standard care” nomogram.20  
In an effort to advance heparin anticoagulation, Schlicht et al. compared the 
Raschke nomogram with an institution-specific modified nomogam to achieve 
therapeutic aPTTs.  The authors were able to demonstrate a reduction in time to 
achieve therapeutic aPTT’s while simultaneously reducing the risk of over 
anticoagulation (as evaluated based on aPTT values >90 secs).21 It should be 
noted that the Raschke nomogram was built on the premise of rapidly achieving 
aPTTs of 1.5-2.5 times the control which may not be appropriate for all heparin 
indications and modification of institutional protocols based on indications may 
help optimize anticoagulation.  
Despite protocol development through titration to specific anticoagulant markers, 
little data exists on how effective protocols are at maintaining therapeutic 
anticoagulation.  Kim et al. tried to demonstrated the effectiveness of 
unfractionated heparin through assessment of achieving and maintain therapeutic  
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aPTT as well as adequacy of the hospital nomogram.22 Their results demonstrated 
a high percentage of patients achieving a therapeutic range at 24 hours (69.5%; 
n=91) and 48 hours (90.1%; n=18) with a therapeutic aPTT proportion of only 
39.2%.   
Aarab et al. evaluated UFH in critically ill patients requiring anticoagulation for a 
variety of indications.23 Time to therapeutic range was 24 hours in 56% of the 101 
patients admitted to the ICU and medium care unit.  The results within the current 
analysis demonstrated that irrespective of the cohort the overall time within 
therapeutic range was less than 50%.  Additionally, following the first therapeutic 
aPTT value, irrespective of the group, the time in therapeutic range was only 
approximately 50%.  Several centers have reported heparin protocol development 
for use in various MCS devices but to our knowledge there hasn’t been a study 
discussing effectiveness of individual protocols within the LVAD population.24-26 
One of the difficulties with utilizing aPTT values to assess for heparin effectiveness 
relates to the broadness of the aPTT test.  There are a variety of disease states 
and factors that can influence the aPTT value, many of which are seen within the 
advanced heart failure and LVAD population.27 In fact, the aPTT test provides a 
better representation of overall coagulopathy as opposed to heparin concentration.  
Our study showed that patients were within therapeutic range only 40.4% of the 
time with only 34.7% of aPTT values being therapeutic.  Somewhat surprisingly, 
there was not a noticeable difference in time within therapeutic range 44.2% with 
only 39.9% of tests within range in the readmission cohort.  Upon achieving a 
therapeutic aPTT maintenance of therapeutic anticoagulation was only 
demonstrated 50% of the time, irrespective of cohort analyzed.  These data 
suggest that while significant improvements can be made with heparin monitoring 
and dosing, they are consistent to previously reported heparin protocols.22,,23  The 
use of anti-factor Xa levels for monitoring systemic heparin anticoagulation has 
been discussed as a better marker for heparin effect on anticoagulation.28 Several 
studies, outside the MCS population, have demonstrated less dose titrations and 
more consistent anticoagulation with the anti-factor Xa test.29-31 Additionally, with 
mechanical circulatory devices patients, it has been reported that there exists a 
significant discordance between the two monitoring tests which raises the question 
of which should be utilized to adjust and monitor heparin.32 In a patient population 
with potential ongoing coagulopathy, the use of a sole marker to monitor 
anticoagulation may negatively impact patient care and predispose patients to 
bleeding or thrombotic events.  Further research is required to elucidate the best 
monitoring strategy in a very dynamic patient population. 
There are several limitations of this study that merit mentioning including the 
retrospective nature of the design.  First, while the authors tried to develop a study 
protocol that objectively assessed patient management through defining heparin 
protocol procedures, the analyses are limited by the retrospective nature of the 
study and the reliance of documentation by the medical team.  Additionally, patient 
management strategies could evolve based on physician experience (presenting a 
historical bias) or could change based on clinical scenario.  These factors provide 
a potential confounder if included, as changes in protocol could be the result of 
increased bleeding or thrombosis risk leading the clinician to modify therapeutic 
targets.  The authors felt that the retrospective nature of the study and reliance on 
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documentation prevented a clear association between protocol changes and 
rationale behind changes.  Therefore, in an effort to eliminate this limitation, the 
authors chose to exclude patients who had protocol modifications.  It is important 
to note that individual patients may require different degrees of heparin if they are 
at higher or lower risk for bleeding and a single protocol may not be suitable for all 
LVAD patients.  The fact that 73 patients were excluded for various reasons 
speaks to the overall heterogeneity within this patient population, especially with 
respect to INTERMACS score at time of implantation and risk for post-operative 
complications. 
Secondly, the authors did not include the average pump speed or range of pump 
speed, which has been associated with outcomes.  The authors felt that without a 
prospective protocol in place the association between pump speeds and heparin 
anticoagulation would be difficult to address.  Further, due to a potential change in 
management practice as a result of patient inclusion into the PREVENT study, we 
did not feel this information would be beneficial.   
Finally, as the primary emphasis of this study was to evaluate the effectiveness of 
the AF/stroke prophylaxis heparin protocol on achieving and maintaining 
therapeutic anticoagulation, assessment of differing protocols on clinical outcomes 
was not possible.  Given the small sample size of this analysis, a direct 
comparison would unlikely be powered to distinguish any differences in outcomes. 
However, this analysis should be utilized as a starting point for subsequent 
analyses addressing the question of how differences in heparin protocols may 
influence clinical outcomes. 
Conclusion 
Patients initiated on heparin atrial fibrillation and stroke prevention protocol only 
achieved therapeutic anticoagulation approximately 40% of the time.  Even after 
patients achieved a therapeutic aPTT, time in therapeutic range was only 48.7%; 
however, despite these seemingly low values the demonstrated risk of thrombosis 
was similar to published literature.  Individual centers should perform ongoing 
assessment of effectiveness of individual heparin protocol for LVAD to ensure 
anticoagulation is optimized in these highly complex patients.   
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